期刊文献+

分子靶向药物在胃肠道肿瘤综合治疗中的应用

Application of Molecular Targeted Agents in Comprehensive Treatment of Gastrointestinal Cancer
下载PDF
导出
摘要 分子靶向药物在胃肠道肿瘤患者中使用,能够有效延长患者的生存期,控制患者的病情,所以,在临床中的重视程度在不断提高。需要进一步研究,制定出适用于胃肠道肿瘤患者的综合治疗模式。本文首先分析靶向药物发展的生物学基础,深入分析临床中常见胃肠道肿瘤综合治疗模式,旨在为临床治疗提供一定的参考。 Molecular targeted drugs used in gastrointestinal cancer patients call effectively prolong patients' life, control the patients' condition. So, the clinical importance is improving, it need fiwther research and treatment to develop a comprehensive treatment model in patients with gastrointestinal tumor. This article at first analyzes the biological basis for the development of targeted drugs, ln-depth analysis of the clinical common comprehensive treatment patteru of gastrointestinal tumor, aims to provide some reference for the clinical treatment.
出处 《中国卫生标准管理》 2015年第30期90-91,共2页 China Health Standard Management
关键词 分子靶向药物 胃肠道肿瘤 综合治疗 Molecular targeted drugs, Gastrointestinal tumors, Comprehensive treatment
  • 相关文献

参考文献6

二级参考文献120

  • 1Marion Peyrou,Lucie Bourgoin,Michelangelo Foti.PTEN in liver diseases and cancer[J].World Journal of Gastroenterology,2010,16(37):4627-4633. 被引量:17
  • 2Monk B J, Sill MW, Burger RA, et al. Phase lI trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study[J]. J Clin Oncol, 2009, 27(7):1069-1074.
  • 3Mackay H J, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184[J]. Gynecol Oncol, 2010, 116(2): 163-167.
  • 4Monk B J, Mas LL, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer[J]. J Clin Oncol, 2010, 28(22):3562-359.
  • 5Nogueira-Rodrigues A, do Carmo CC, Viegas C, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer[J]. Clin Cancer Res, 2008, 14(19):6324-6329.
  • 6Kersemaekers AM, Fleuren GJ, Kenter GG, et al. Oncogene aherations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis[J]. Clin Cancer Res, 1999, 5(3):577-586.
  • 7Fadare O, Zheng W. HER2 protein (p185(HER2)) is only rarely overexpressed in cervical cancer[J]. Int J Gyneeol Pathol, 2004, 23(4):410-1; author reply 411-412.
  • 8Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial[J]. Gyneeol Oncol, 2009, 113(1):16-20.
  • 9Herrera FG, Chan P, Doll C, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment[J]. Int J Radiat Oncol Biol Phys, 2007, 67(1):97-103.
  • 10Gaffney DK, Winter K, Dicker AP, et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128[J]. Int J Radiat Oncol Biol Phys, 2007, 69(1):111-117.

共引文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部